SIV reservoir depletion and clearance from neonatal macaques following transient CCR5 depletion

Abstract Antiretroviral therapy (ART) suppresses viraemia in people with human immunodeficiency virus (HIV), but HIV provirus persists indefinitely in CD4-expressing cells. Cells containing active provirus express viral proteins and have been successfully targeted using broadly neutralizing antibodies (bnAbs). In contrast, cells containing latent provirus cannot be specifically targeted without latency reactivation. Meaningful depletion of the latent HIV or simian immunodeficiency virus (SIV) reservoirs has not been demonstrated except with cytotoxic conditioning for bone-marrow transplantation. Here we show that both the active and latent SIV reservoirs can be eliminated from infant macaques via profound but transient depletion of cells that express CCR5 using a single shot of CCR5/CD3 bispecific antibody. Neonatal rhesus macaques were infected with SIVmac251, then treated with ART beginning at 1 week after infection, followed by treatment with either a CCR5/CD3-bispecific or a CD4-specific antibody, both of which depleted target cells and accelerated the decline in plasma viraemia. Upon ART cessation, while rebound occurred quickly in all animals treated with ART alone, most animals treated with CCR5/CD3 bispecific antibody remained aviraemic for >3 months. Several remained aviraemic to the end of follow-up and efforts to detect replication-competent virus were unsuccessful. Our results show that bispecific antibody treatment achieves meaningful depletion of the replication-competent SIV reservoir and supports the possibility that clinically meaningful depletion of the HIV reservoir might be achievable for recently infected individuals.

Authors

Institutions

Publication Details

Journal
Nature Microbiology
Published
2026-10-19
DOI
https://doi.org/10.1038/s41564-026-02511-3
Primary Topic
HIV Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

SIV reservoir depletion and clearance from neonatal macaques following transient CCR5 depletion

Corey N. Miller, Jacob D. Estes, Dennis J. Hartigan-O’Connor, W. L. William Chang et al.
Nature Microbiology
HIV Research and Treatment
article

SIV reservoir depletion and clearance from neonatal macaques following transient CCR5 depletion

Corey N. Miller, Jacob D. Estes, Dennis J. Hartigan-O’Connor, W. L. William Chang, Elizabeth Heninger, Kawthar Machmach, Bryant Chi-Thien Tran, Jeffrey D. Lifson, Keith A. Reimann, David Merriam, Ning Chin, Wenze Lu, Justin H. Fontaine, Mario Stevenson, Steven G. Deeks, Joseph Dutra, Diogo M. Magnani, Michael D. Nekorchuk, Jesse D. Deere, Gema Méndez‐Lagares, Connie Chen, Hung T. Kieu, Jessica Salinas, Kathleen Engelman, Margaret Martin, Denise R. Andal, Kateland Sipe
article en

Abstract

Abstract Antiretroviral therapy (ART) suppresses viraemia in people with human immunodeficiency virus (HIV), but HIV provirus persists indefinitely in CD4-expressing cells. Cells containing active provirus express viral proteins and have been successfully targeted using broadly neutralizing antibodies (bnAbs). In contrast, cells containing latent provirus cannot be specifically targeted without latency reactivation. Meaningful depletion of the latent HIV or simian immunodeficiency virus (SIV) reservoirs has not been demonstrated except with cytotoxic conditioning for bone-marrow transplantation. Here we show that both the active and latent SIV reservoirs can be eliminated from infant macaques via profound but transient depletion of cells that express CCR5 using a single shot of CCR5/CD3 bispecific antibody. Neonatal rhesus macaques were infected with SIVmac251, then treated with ART beginning at 1 week after infection, followed by treatment with either a CCR5/CD3-bispecific or a CD4-specific antibody, both of which depleted target cells and accelerated the decline in plasma viraemia. Upon ART cessation, while rebound occurred quickly in all animals treated with ART alone, most animals treated with CCR5/CD3 bispecific antibody remained aviraemic for >3 months. Several remained aviraemic to the end of follow-up and efforts to detect replication-competent virus were unsuccessful. Our results show that bispecific antibody treatment achieves meaningful depletion of the replication-competent SIV reservoir and supports the possibility that clinically meaningful depletion of the HIV reservoir might be achievable for recently infected individuals.

Nature Microbiology
Oregon National Primate Research Center (US), Henry M. Jackson Foundation (US), University of Miami (US), Oregon Health & Science University (US), University of Massachusetts Chan Medical School (US), University of California, San Francisco (US), Frederick National Laboratory for Cancer Research (US), Vaccine and Gene Therapy Institute, University of California, Davis (US), Walter Reed Army Institute of Research (US)
Openalex Percentile: Top 15%
HIV Research and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.